Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease

NCT03402659 is registered in ClinicalTrials.gov with EIP Pharma Inc as lead sponsor.

NCT NCT03402659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03402659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Lead sponsor
EIP Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
December 29, 2017
Completion date
July 31, 2019
Enrollment
161 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease